Source-grounded facts extracted from Axsome Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.
“Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.”
Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.
“Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.